Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Svetinorm iconSvetinormSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Svetinorm

Beginner tier: 10 mg, daily · 4w on / 16w off · community consensus

MetabolicResearch
~0.5-1 hour half-life (estimated)·Oral

Also known as: A-7, KEDA (active component), Livagen (related)

Forty-seven patients with chronic hepatitis and post-chemotherapy liver damage. That's the entire human evidence base for Svetinorm, an oral peptide bioregulator from Russia's Institute of Bioregulation and Gerontology. The peptide complex A-7 contains KEDA (Lys-Glu-Asp-Ala), a tetrapeptide that targets hepatocyte DNA and reactivates age-silenced genes tied to liver detoxification. ALT and bilirubin stabilized by week three in that single study. No randomized controlled trial has followed. Longevity-focused users still run 30-day courses two to three times per year, tracking liver panels to confirm what bloodwork alone can verify.

What Is Svetinorm?

Svetinorm (peptide complex A-7) is a mixture of low-molecular-weight peptides (under 10 kDa) extracted from young calf liver tissue, designed to support hepatocyte gene expression. Forty-four indexed PubMed citations exist, zero randomized controlled trials, and one clinical study from a single research group. It was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Prof. Vladimir Khavinson, who spent decades building a library of organ-specific bioregulators. The active component is believed to include the tetrapeptide KEDA (Lys-Glu-Asp-Ala), also sold separately as Livagen.

How it works at the cellular level is actually well mapped. KEDA penetrates hepatocyte nuclei and binds DNA promoter regions, causing heterochromatin decondensation at ribosomal gene loci on chromosomes 1, 9, and 16. That reactivates genes silenced by age-related chromatin compaction. Downstream, CYP450 phase I enzymes, glutathione S-transferase, and albumin synthesis all increase in preclinical models [1].

The clinical picture is thin. Khavinson's 2003 to 2004 study enrolled 47 patients with chronic hepatitis and post-chemotherapy liver injury. Those receiving Svetinorm showed stabilized ALT and bilirubin, plus decreased IgM [2]. No placebo arm. No blinding. No Western replication. Prof. Khavinson died in January 2024; no new primary research has appeared since.

Users who run Svetinorm tend to be longevity enthusiasts already familiar with the Khavinson bioregulator system. Most follow the published protocol exactly: 10 to 20 mg daily for 30 days, off for four to six months, repeated two to three times per year. Without baseline liver panels, distinguishing a real response from placebo is functionally impossible.

How Svetinorm Works

KEDA (Lys-Glu-Asp-Ala), the tetrapeptide believed to be Svetinorm's active component, shows tissue-specific affinity for hepatocytes. Once inside the cell, it crosses the nuclear membrane and interacts with DNA promoter regions through complementary binding. This causes local unwinding of the double helix, activating RNA polymerase-driven transcription at sites that had gone quiet.

The specific epigenetic change is heterochromatin decondensation. In aged liver cells, ribosomal gene loci on chromosomes 1, 9, and 16 become compacted, silencing protein synthesis. KEDA reverses that compaction, essentially turning those genes back on. Khavinson's group confirmed this in organotypic liver cultures from old rats, where KEDA restored protein synthesis rates to levels comparable to young tissue [1].

Downstream effects are broad. CYP450 phase I detoxification enzymes get upregulated, increasing the liver's capacity to metabolize xenobiotics. Glutathione S-transferase (GST) and UDP-glucuronosyltransferase (UGT) activity increases for phase II conjugation. Albumin output rises. The peptide also modulates hepatocyte growth factor (HGF) receptor expression, which supports liver regeneration after injury [3].

All of this comes from preclinical work. The jump from rat organotypic cultures to human hepatocytes in vivo is large, and no formal pharmacokinetic study has confirmed whether oral KEDA reaches the liver in bioactive concentrations.

Svetinorm Benefits

  • Svetinorm benefits center on hepatoprotective support and liver cell renewal, though the evidence base remains narrow.
  • ALT and bilirubin stabilization observed in 47 patients with chronic hepatitis and post-chemotherapy liver damage during the only clinical study [2].
  • IgM reduction during the same trial pointed to decreased inflammatory activity in diseased liver tissue.
  • CYP450 phase I and glutathione S-transferase phase II enzyme upregulation confirmed in preclinical hepatocyte models, supporting detoxification capacity [1].
  • Protein synthesis restoration in aged rat liver cultures brought output back to levels matching young tissue; one of the cleaner preclinical findings in the KEDA literature [1].
  • Well tolerated across all available data, with no serious adverse events documented in the clinical study, community reports, or preclinical literature.
  • Oral capsule format eliminates injection-related barriers, making it one of the few peptide bioregulators that requires no reconstitution or needles.

Svetinorm: Science vs Community Consensus

Aligned
Scientific Evidence
Weak
Based on 6 key studies·Research only

Hepatoprotective effects (ALT/bilirubin stabilization, IgM reduction) observed in a single uncontrolled clinical study (n=47, chronic hepatitis and post-chemo populations, Khavinson Institute 2003–2004).

Dosing studied: 10–20 mg/day (1–2 oral capsules) for 20–30 days, 2–3x/year
Read the evidence (key study, limitations)

Mechanistic data (KEDA epigenetic chromatin remodeling, CYP450/GST upregulation, HGF receptor modulation) supported by in vitro and animal models. No RCTs. No placebo control. No Western replication. Primary investigator deceased Jan 2024; no new primary research published since.

Key Study

PMID 32362099: "The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology." Adv Gerontol, 2020. Most recent indexed study directly on KEDA/A-7 complex; covers animal hepatitis models and human aging data.

Limitations

No RCTs. No blinding or placebo control in the clinical study. Single research group (Khavinson Institute). Proprietary A-7 composition not publicly disclosed. No formal PK data for KEDA or Svetinorm. No Western-journal clinical trials. Primary investigator (Khavinson) deceased Jan 2024; new research pipeline stalled. Aggressive tier (40 mg/day) exceeds conservative Firma Vita maximum of 2 caps 2x daily.

Community Experience
Weak
3.5/5
Based on near-zero Reddit mentions (r/peptides, r/nootropics, r/longevity)

Niche use confined to longevity and Khavinson bioregulator enthusiasts.

Community dosing: 10–20 mg/day (1–2 caps) 1–2x daily with meals, 20–30 days, 2–3x/year
Read the reports (what users report 4, common issues 4)

Subjective reports of improved energy and digestion during the 30-day course. Too few independent user reports to characterize effect reliability. Community confidence largely derived from the Khavinson clinical literature rather than independent user experience.

What users report (4)
  • Improved energy and reduced fatigue during the active course
  • Subjective digestive improvement reported by some users
  • Well-tolerated: no serious adverse events reported in community use
  • Liver enzyme stabilization (ALT, bilirubin) cited from Khavinson study by informed users
Common issues (4)
  • Near-zero independent user reports: almost impossible to separate peptide effect from placebo without bloodwork
  • Long off-period (4–6 months) makes perceived benefit attribution difficult
  • High cost relative to well-studied alternatives (milk thistle/silymarin has far stronger RCT evidence)
  • Limited Western sourcing transparency; authenticity risk from gray-market resale
Science & Community Aligned

Community dosing and stated outcomes closely mirror the Khavinson Institute protocol: because most users derive their approach directly from that literature rather than independent experimentation. True independent alignment cannot be confirmed given the near-zero community self-report pool. The agreement is methodological (adopting the published protocol) rather than empirical (independent verification of outcomes).

Svetinorm Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner10 mgDaily
Moderate10 mg2x Daily
Aggressive20 mg2x Daily
Note:

Svetinorm ships as oral capsules. No reconstitution, no syringes, no bacteriostatic water. Each capsule contains 10 mg of peptide complex A-7.

Bottles come in 20-cap and 60-cap sizes. A 60-cap bottle covers one full 30-day course at 2 caps per day. The 20-cap bottle only lasts 10 days at that dose, so you'll need three of them for a complete course.

Take capsules with meals. The manufacturer and the Khavinson protocol both specify mealtime dosing; empty-stomach use is the main trigger for the mild GI discomfort some users report.

Get a liver panel (ALT, AST, bilirubin) before your first capsule. Get another at the end of the 30-day course. Without those two data points, you're flying blind on whether anything actually changed.

The off-period matters. Four to six months between courses is not a suggestion; it's the core premise of the bioregulator approach. KEDA triggers epigenetic changes that are supposed to persist after the compound clears. Restarting early undermines the protocol's theoretical basis.

Cycling Protocol

On Period
4 weeks
Off Period
16 weeks

Standard Khavinson bioregulator protocol: 20-30 days on, then off for 4-6 months. Repeat 2-3 times per year. The long off-period allows endogenous regulatory mechanisms to stabilize. Limited data on optimal cycling duration.

Calculate your Svetinorm dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Svetinorm Protocols by Goal

beginnerClinical Trial20–30 days
Standard Khavinson course
Wk 3–4
10–20 mg · Once to twice daily with meals · Oral

Expected: Possible ALT and bilirubin stabilization measurable on bloodwork by week 2–3 (primarily in individuals with elevated baseline liver enzymes); subtle energy and digestive improvement; no dramatic subjective response expected in healthy individuals

Monitor: Obtain baseline ALT, AST, and bilirubin before starting. Retest at end of the 30-day course. No objective bloodwork improvement after one course warrants reassessment before repeating.

How to Use Svetinorm

  1. 1
    Obtain baseline bloodwork

    Request ALT, AST, and total bilirubin from your physician or a direct-to-consumer lab. Record your results before starting.

  2. 2
    Step 2

    Open the bottle and take 1 capsule (10 mg) with your largest meal on Day 1. This is a tolerance check. Swallow whole with water.

  3. 3
    Step 3

    From Day 2 onward, take 1 capsule (10 mg) twice daily with meals (breakfast and dinner) for the standard protocol. For the conservative maintenance tier, 1 capsule once daily is sufficient.

  4. 4
    Continue for 20 to 30 days

    A 60-capsule bottle covers a full 30-day course at 2 capsules per day.

  5. 5
    No injection equipment is needed

    No reconstitution. No refrigeration required during the course. Store capsules at room temperature (15 to 25 degrees Celsius) in a dry place away from direct sunlight.

  6. 6
    At the end of the course, repeat your liver panel

    Compare ALT, AST, and bilirubin to baseline values. No measurable change after one course is common in healthy individuals; changes are more detectable if baseline values were raised.

  7. 7
    Wait 4 to 6 months before running the next course

    Plan 2 to 3 courses per year. Do not restart early.

Alternative Routes

Sublingual (lingual tablet)

No published pharmacokinetic comparison between oral capsule and sublingual form; same dose convention (10 mg units) used for the sublingual format

Sublingual form sold as a specialty bioregulator product. Some community members prefer it on the theory that sublingual absorption bypasses first-pass hepatic metabolism and increases bioavailability of small peptides. No PK study has been published comparing the two routes for Svetinorm or KEDA. The standard oral capsule form is the only route with any clinical study backing.

Svetinorm Stacking Protocols

Works With

Avoid

Immunosuppressants (cyclosporine, tacrolimus, mycophenolate)

Svetinorm reduced IgM (an immune marker) in the Khavinson clinical study. Combining with immunosuppressants in transplant recipients is theoretically risky and insufficiently studied.

Do not combine
NSAIDs (ibuprofen, naproxen, diclofenac)

NSAIDs are among the most common causes of drug-induced liver injury. Concurrent use adds hepatotoxic burden during a liver-support protocol.

Statins (atorvastatin, simvastatin, rosuvastatin)

Statins carry hepatotoxic risk (transaminase elevation); monitoring liver enzymes is especially important if combining with Svetinorm.

Anticoagulants (warfarin, heparin)

KEDA tetrapeptide has shown effects on blood clotting and fibrinolysis in preclinical models; theoretical interaction with anticoagulant therapy. No clinical data to characterize the risk.

Estimated Cost

Brand Price
Firma Vita (manufacturer) capsules: market prices run $52–$55 per 20 caps and $129.99–$135 per 60 caps. Per-capsule cost: ~$2.25–$2.75 USD per 10 mg capsule.

Pricing updated 2026-04-09

Svetinorm Side Effects

The safety dataset for Svetinorm is too small to characterize a reliable side-effect profile. The entire human evidence base comes from one uncontrolled clinical study of 47 patients at the Khavinson Institute (2003 to 2004), plus a near-zero pool of independent community reports. That is not enough to detect rare adverse events.

No serious adverse effects were documented in the available literature. The clinical study reported no treatment-related safety signals in either the chronic hepatitis or post-chemotherapy cohorts. Community users on Longecity forums and practitioner blogs consistently describe the product as well tolerated. But "no reports" from a sample this small is not the same as "safe."

Mild digestive discomfort is the only side effect mentioned with any consistency. A few users noted GI sensitivity during the first two to three days when capsules were taken on an empty stomach. Taking Svetinorm with meals appears to resolve this, and the manufacturer's instructions specify mealtime dosing.

The KEDA tetrapeptide showed effects on blood clotting and fibrinolysis in preclinical models. Anyone taking anticoagulants (warfarin, heparin) should flag this to their physician. No clinical data exists to quantify the interaction risk, but the preclinical signal warrants caution.

Svetinorm reduced IgM levels in the clinical study, which is a marker of immune activity. For transplant recipients on immunosuppressants like cyclosporine or tacrolimus, this creates a theoretical additive immunosuppressive effect. That combination has not been studied and should be avoided without specialist oversight.

Liver function worsening has not been documented, but the entire premise of taking a liver bioregulator assumes you're monitoring liver function. If ALT or AST rise during or after a course, stop and consult a hepatologist.

Pregnancy and breastfeeding are contraindicated. No reproductive safety data exists. Children under 14 have not been studied. Anyone with active liver failure or decompensated cirrhosis lacks data to support use in that population.

The honest summary: Svetinorm appears well tolerated in limited observation, but the observation is genuinely limited. Bloodwork before and after each course is the only way to catch a problem early.

Common Issues & Solutions

No bloodwork change after one course: Confirm capsules were taken with meals (not fasted). A second course 4–6 months later and retesting is required before concluding non-response: single-course non-response is not definitive given the slow epigenetic mechanism.

Cannot distinguish benefit from placebo: Without baseline ALT/AST/bilirubin, effect attribution is impossible. Always get a liver panel before and after the course. Subjective energy improvement alone is not a reliable efficacy signal.

Aggressive tier concern (40 mg/day = 4 caps/day): This exceeds the conservative Firma Vita maximum. No serious AEs documented at this dose in limited literature, but it is outside the validated range. Limit to 20 mg/day without physician oversight familiar with bioregulators.

Authenticity: legitimate product traces to Firma Vita through a documented supply chain. Online marketplace listings have unverifiable provenance. The legitimate product has a 30+ year track record; counterfeits/subpotent alternatives do not.

Off-period impatience: The 4–6 month rest between courses is not optional: it is mechanistically central to the Khavinson protocol. Early restart is inconsistent with the epigenetic stabilization premise.

Ask AI about this page

Ask AI for a second opinion on Svetinorm dosing and side effects

Contraindications

  • Pregnancy or breastfeeding (no safety data available)
  • Known allergy to animal-derived peptide products
  • Active liver failure or decompensated cirrhosis (insufficient data for severe disease)
  • Children under 14 (not studied in pediatric populations)
  • Organ transplant recipients on immunosuppressants (theoretical interaction concern)

Drug Interactions

  • Immunosuppressants: Svetinorm may modulate immune markers; monitor if on cyclosporine, tacrolimus, or similar agents
  • Hepatotoxic medications: theoretical additive liver stress if combined with known hepatotoxins; monitor liver enzymes
  • Anticoagulants: KEDA peptide has shown effects on blood clotting and fibrinolysis in preclinical models; use caution with warfarin or heparin
  • No formal drug interaction studies have been conducted
  • NSAIDs are among the most common causes of drug-induced liver injury. Concurrent use adds hepatotoxic burden during a liver-support protocol.
  • Anticoagulants (warfarin, heparin)
  • KEDA tetrapeptide has shown effects on blood clotting and fibrinolysis in preclinical models; theoretical interaction with anticoagulant therapy. No clinical data to characterize the risk.

Product Quality

Recommended Monitoring

TestWhenTarget
ALT (Alanine Aminotransferase)Baseline before each course; end of 30-day course; optional 3-month post-course<40 U/L (normal); response defined as trend toward normal from an elevated baseline
AST (Aspartate Aminotransferase)Baseline before each course; end of 30-day course<40 U/L (normal)
Total BilirubinBaseline before each course; end of 30-day course0.1–1.2 mg/dL (normal)
IgM (Immunoglobulin M)Optional; baseline and end of course if monitoring inflammatory statusNot listed
ALT (Alanine Aminotransferase)

Primary endpoint in the Khavinson clinical study; key marker for hepatoprotective effect. Required to distinguish real response from placebo.

AST (Aspartate Aminotransferase)

Companion liver enzyme marker; helps distinguish hepatocellular injury from biliary or other causes

Total Bilirubin

Second primary endpoint in Khavinson study; elevated bilirubin indicates hepatocyte dysfunction; stabilization expected during course in disease populations

IgM (Immunoglobulin M)

Decreased IgM was an observed secondary outcome in the Khavinson hepatitis study, indicating anti-inflammatory activity; not a standard liver panel component

Svetinorm Before and After

Days 1-7

No noticeable external changes expected. Peptide-DNA interactions begin at the cellular level. Gene transcription changes are accumulating in hepatocytes but won't be perceptible.

Weeks 2-3

Some users anecdotally report improved energy and digestion. In the clinical study, biochemical markers (ALT, bilirubin) began stabilizing during this phase. Effects are subtle and difficult to distinguish from placebo.

Week 4
end of course

End of standard on-cycle. The clinical study showed measurable stabilization of liver enzymes and decreased IgM levels by this point. Improvements in liver function tests may be confirmable via bloodwork.

Months 2-6
off-cycle

Bioregulator theory holds that epigenetic changes persist after discontinuation. Liver enzyme levels should remain stable. Plan the next course for 4-6 months later.

What to Expect

Days 1 through 7: Nothing perceptible. KEDA-DNA interactions are initiating inside hepatocytes, and heterochromatin at ribosomal gene loci on chromosomes 1, 9, and 16 is starting to decondense. CYP450 and GST transcription changes accumulate silently. Mild GI sensitivity is possible if you skip the "with meals" instruction. Most users report exactly zero changes during this window.

Weeks 2 through 3: The clinical study data picks up here. ALT and bilirubin began stabilizing in the hepatitis and post-chemotherapy patients by this phase [2]. Some community users mention improved energy and appetite, though these reports are subtle and hard to separate from placebo without bloodwork. Protein synthesis upregulation is accumulating in hepatocytes, but you won't feel that directly.

Week 4 (end of course): The finish line for a standard on-cycle. The Khavinson study showed measurable ALT, bilirubin stabilization, and decreased IgM by this point, but only in populations that started with abnormal baselines. Healthy individuals may see no detectable shift on bloodwork. Get your post-course liver panel now.

Months 2 through 6 (off-cycle): Bioregulator theory holds that the epigenetic changes, chromatin remodeling and transcription activation, persist after the peptide clears. Liver enzyme improvements should hold through the off-period. Subjective effects gradually return toward baseline for most users. Plan the next course at the four to six month mark. Do not restart early.

Detailed Timeline: Science vs Community

Days 1–7
Science

KEDA-DNA interactions initiating in hepatocytes; heterochromatin decondensation at ribosomal gene loci (chromosomes 1, 9, 16) beginning; CYP450 and GST transcription changes accumulating: no detectable biochemical shift at this stage

Community

Nothing noticeable; occasional mild GI sensitivity in the first 2–3 days if taken without food

Weeks 2–3
Science

ALT and bilirubin stabilization begins in hepatitis/post-chemo populations based on Khavinson 2003 data; protein synthesis upregulation accumulating in hepatocytes

Community

Some users report improved energy and appetite; effects are subtle and easily confounded with placebo without baseline bloodwork comparison

Week 4 (end of course)
Science

ALT and bilirubin stabilization, and decreased IgM, observed by this point in Khavinson clinical study (disease populations only). Healthy-individual biochemical response unknown.

Community

Subjective energy improvement may persist; users encouraged to get a post-course liver panel to confirm objective response

Months 2–6 (off-cycle)
Science

Bioregulator theory: chromatin remodeling and transcription activation persist after peptide clearance; liver enzyme improvements expected to be maintained through the off-period without additional dosing

Community

Subjective effects return toward baseline gradually; most users plan the next course at 4–6 months and do not experience relapse of symptoms during the off-period

Pharmacokinetics

Half-Life
30min
Bioavailability
Oral: not formally characterized; likely low but proposed active at epigenetic-level doses
Tmax
Unknown: no formal PK study published
Data Confidence
low

Source: Estimated from tetrapeptide class pharmacokinetics. No direct PK study exists for Svetinorm or KEDA. Short peptides (2-4 amino acids) are rapidly degraded by peptidases within minutes to an hour.

Pharmacokinetics: Active Dose Over Time

t½ = ~0.5-1 hour (estimated from tetrapeptide class)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Svetinorm

  • Adults over 40 with age-related liver function decline
  • Individuals recovering from chemotherapy or radiation therapy
  • Those with chronic hepatitis seeking adjunctive support (under medical supervision)
  • Health-optimizers interested in liver detoxification support
  • Researchers studying Khavinson bioregulator peptides

Related Peptides

What Changed for Svetinorm

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen (Izv Akad Nauk Ser Biol 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology (Adv Gerontol, 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Functional morphology of an organotypic liver culture exposed to the peptide Livagen (Bull Exp Biol Med, 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store sealed capsules at room temperature in a dry place, away from direct sunlight
After Reconstitution
N/A: oral capsule formulation, no reconstitution required
Temperature
15-25°C (59-77°F)

Frequently Asked Questions

Related but not identical. KEDA (Lys-Glu-Asp-Ala) is the specific tetrapeptide believed to be the active component in Svetinorm's A-7 complex, and Livagen contains KEDA. But A-7 is a proprietary polypeptide complex extracted from calf liver: its full composition isn't publicly disclosed. Svetinorm may contain KEDA plus other liver-derived peptides.

The Khavinson clinical study observed measurable ALT and bilirubin stabilization by weeks 2-3. Subjective improvements (energy, digestion) are reported around the same timeframe, but they're subtle and hard to distinguish from placebo without bloodwork. Get baseline liver function tests (ALT, AST, bilirubin) before starting so you can track objective changes.

Bioregulator theory holds that epigenetic changes persist beyond the compound's presence. Limited clinical data suggests ALT stabilization was maintained at follow-up. The Khavinson protocol's long off-period (4-6 months) is based on this premise. That said, independent verification is lacking.

NAFLD isn't a listed contraindication, and the hepatoprotective mechanism (HGF receptor upregulation, phase I/II enzyme support) is arguably most relevant to NAFLD patients. But there are no NAFLD-specific studies. Use under medical supervision and monitor liver enzymes quarterly.

It slightly exceeds the Firma Vita recommendation of 2 caps 1-2x daily max. No serious adverse effects were reported at any dose in the limited literature, but 40 mg/day exceeds the validated range. Stick to 20 mg/day (2 capsules) unless a physician familiar with bioregulators tells you otherwise.